Header cover image

Hong Kong (HSI) Healthtech Industry Analysis

UpdatedApr 18, 2024
DataAggregated Company Financials
Companies6
  • 7D-8.4%
  • 3M-2.3%
  • 1Y-28.3%
  • YTDn/a

Over the last 7 days, the Healthtech industry has dropped 8.4%, driven by Medlive Technology declining 11%. The industry has fallen 28% in the last year. Looking forward, earnings are forecast to grow by 28% annually.

Industry Valuation and Performance

Has the Hong Kong Healthtech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 19 Apr 2024HK$15.1bHK$2.8b-HK$257,537,580.6421.1x-58.5x5.4x
Sun, 17 Mar 2024HK$15.3bHK$2.1b-HK$173,371,148.6326.5x-88x7.2x
Tue, 13 Feb 2024HK$13.5bHK$2.1b-HK$173,371,687.3523.1x-77.8x6.4x
Thu, 11 Jan 2024HK$15.5bHK$2.1b-HK$173,974,287.0025.4x-89x7.3x
Sat, 09 Dec 2023HK$17.1bHK$2.1b-HK$173,980,606.0027.9x-98.6x8.1x
Mon, 06 Nov 2023HK$16.0bHK$2.2b-HK$468,250,765.0029.2x-34.2x7.2x
Wed, 04 Oct 2023HK$16.8bHK$2.2b-HK$469,044,260.0027.7x-35.8x7.6x
Fri, 01 Sep 2023HK$15.4bHK$2.2b-HK$470,598,728.0025x-32.8x7x
Sun, 30 Jul 2023HK$14.0bHK$1.7b-HK$692,192,637.0037.2x-20.3x8.1x
Tue, 27 Jun 2023HK$14.3bHK$2.2b-HK$738,798,733.0033.2x-19.3x6.6x
Thu, 25 May 2023HK$13.4bHK$2.2b-HK$757,548,831.0035.5x-17.7x6x
Sat, 22 Apr 2023HK$16.9bHK$2.3b-HK$777,080,624.0040.4x-21.7x7.4x
Mon, 20 Mar 2023HK$19.5bHK$2.2b-HK$873,102,298.0088.7x-22.4x8.8x
Wed, 15 Feb 2023HK$22.2bHK$2.6b-HK$973,435,764.0084.8x-22.8x8.7x
Fri, 13 Jan 2023HK$18.8bHK$2.6b-HK$977,073,811.0074.4x-19.3x7.4x
Sun, 11 Dec 2022HK$20.4bHK$2.5b-HK$947,661,350.0086.3x-21.5x8.2x
Tue, 08 Nov 2022HK$16.6bHK$2.5b-HK$1,023,566,214.0070.2x-16.2x6.7x
Thu, 06 Oct 2022HK$17.1bHK$2.5b-HK$1,032,619,225.0075.8x-16.6x6.9x
Sat, 03 Sep 2022HK$20.8bHK$2.5b-HK$1,038,372,922.0089.1x-20x8.2x
Mon, 01 Aug 2022HK$19.5bHK$2.2b-HK$1,089,561,226.00151.1x-17.9x8.8x
Wed, 29 Jun 2022HK$23.5bHK$2.2b-HK$1,096,855,568.00195.5x-21.4x10.5x
Fri, 27 May 2022HK$17.4bHK$2.0b-HK$3,682,274,691.00122.9x-4.7x8.6x
Sun, 24 Apr 2022HK$18.9bHK$2.1b-HK$3,764,833,797.00123.1x-5x9.1x
Tue, 22 Mar 2022HK$84.5bHK$23.9b-HK$4,002,755,057.0088.5x-21.1x3.5x
Thu, 17 Feb 2022HK$108.3bHK$23.8b-HK$3,846,214,702.0090.9x-28.1x4.5x
Sat, 15 Jan 2022HK$137.2bHK$23.7b-HK$3,826,690,790.00181.4x-35.9x5.8x
Mon, 13 Dec 2021HK$149.8bHK$23.6b-HK$3,750,762,277.00304.8x-39.9x6.4x
Wed, 10 Nov 2021HK$176.6bHK$20.5b-HK$4,014,172,073.00311.2x-44x8.6x
Fri, 08 Oct 2021HK$200.2bHK$20.4b-HK$3,986,669,129.00329.6x-50.2x9.8x
Sun, 05 Sep 2021HK$239.6bHK$20.0b-HK$3,909,505,616.11364.3x-61.3x12x
Tue, 03 Aug 2021HK$215.8bHK$20.0b-HK$3,909,505,616.11320.8x-55.2x10.8x
Fri, 07 May 2021HK$361.6bHK$19.7b-HK$3,994,084,908.29772.3x-90.5x18.3x
Price to Earnings Ratio

-90.5x


Total Market Cap: HK$361.6bTotal Earnings: -HK$3,994,084,908.29Total Revenue: HK$19.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Hong Kong Healthtech Industry Price to Earnings3Y Average -39.1x202220232024
Current Industry PE
  • Investors are pessimistic on the Hong Kong Health Care Technology industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 8.4x is higher than the industry's current PS ratio of 5.4x.
Past Earnings Growth
  • The earnings for companies in the Health Care Technology industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 48% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Comparison

How does Hong Kong Healthtech compare with similar industries?

HK Market-2.76%
Healthcare-4.52%
Healthtech-8.36%
Healthtech-8.36%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
6819 IntelliCentrics Global HoldingsHK$4.071.8%
+HK$31.7m
-18.6%PS5.4x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.